VKORC1
Vitamin K epoxide reductase complex subunit 1
As of the edition of 20 October 2026, VKORC1 (vitamin K epoxide reductase complex subunit 1, UniProt Q9BQB6) has 6 drugs tested at it and 13 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9BQB6
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Heart and blood vessels; Nervous system; Nutrition and metabolism; Digestive system; Lungs and airways; Cancer; Urinary and reproductive; Skin and connective tissue
- Registered trials of its drugs
- 278
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Warfarin | Marketed | Phase 4 | none listed |
| Acenocoumarol | Marketed | Phase 4 | none listed |
| Phenprocoumon | Marketed | Phase 4 | none listed |
| Tecarfarin | Went quiet | Phase 3 | none listed |
| Dicumarol | Marketed | No phase stated | none listed |
| Phenindione | Marketed | Phase 3 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Engaged | 4 |
| Undetermined | 4 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Eisai | Route B |
| Sanofi | Route B |
| Espero Biopharma | Route A |
The other 10 companies at VKORC1
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at VKORC1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.